Source: International Congress 2015 – Pulmonary hypertension: management
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Fabienne Goncalves (Oporto, Portugal), Fabienne Gonçalves, Ana Gomes, Célia Cruz, Inês Furtado, Margarida Vicente, Luísa Carvalho, Mário Santos, Abílio Reis. Transitioning sildenafil to taladafil in PAH patients is safe. Eur Respir J 2015; 46: Suppl. 59, 3781

Member's Comments

No comment yet.

Related content which might interest you: Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Adherence to pulmonary arterial hypertension targeted therapies Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Intravenous prostacyclin for pulmonary hypertension: Patient’s perspective on complications Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide Source: International Congress 2014 – Clinical presentations Year: 2014 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015